Neostigmine

Generic Name
Neostigmine
Brand Names
Bloxiverz, Prevduo, Prostigmin
Drug Type
Small Molecule
Chemical Formula
C12H19N2O2
CAS Number
59-99-4
Unique Ingredient Identifier
3982TWQ96G
Background

A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike physostigmine, does not cross the blood-brain barrier.

Indication

Neostigmine is used for the symptomatic treatment of myasthenia gravis by improving muscle tone.

Associated Conditions
Curarization therapy, Myasthenia Gravis, Neuromuscular Blockade, Postoperative Urinary Retention (POUR), Acute Colonic Pseudo-Obstruction, Post-operative intestinal atony
Associated Therapies
-
Clinical Trials
Related News

Comparison of QoR-15 in Laparoscopic Cholecystectomy: Sugammadex vs. Neostigmine

First Posted Date
2020-04-02
Last Posted Date
2020-12-24
Lead Sponsor
Seoul National University Bundang Hospital
Target Recruit Count
77
Registration Number
NCT04332627
Locations
🇰🇷

Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of

The Effect of Intraperitoneal Bupivacaine Versus Bupivacaine With Neostigmine on Pain in Laparoscopic Cholecystectomy

First Posted Date
2020-01-28
Last Posted Date
2020-09-03
Lead Sponsor
Kasr El Aini Hospital
Target Recruit Count
56
Registration Number
NCT04244097
Locations
🇪🇬

Sara Farouk Kassem Habib, Cairo, El Azbakeya, Egypt

Adjuvant Use of Neostigmine in Sepsis and Septic Shock.

First Posted Date
2019-10-17
Last Posted Date
2024-07-10
Lead Sponsor
Mansoura University
Target Recruit Count
50
Registration Number
NCT04130230
Locations
🇪🇬

Tanta University Hospital, Tanta, EL-Gharbia, Egypt

Different Reversal Agents in Pediatric Day-case Cancer Surgery

First Posted Date
2019-06-25
Last Posted Date
2019-06-25
Lead Sponsor
National Cancer Institute, Egypt
Target Recruit Count
80
Registration Number
NCT03996655

Efficacy and Safety of Sugammadex in High-Risk Ambulatory Surgeries

Phase 4
Withdrawn
Conditions
Ambulatory Difficulty
Interventions
Drug: Neostigmine
Drug: Sugammadex
First Posted Date
2019-05-09
Last Posted Date
2019-11-18
Lead Sponsor
Montefiore Medical Center
Registration Number
NCT03944473

Role of Sugammadex as Reversal Agent in Patients Extubated Immediately After Isolated Coronary Artery Bypass Grafting Surgery

First Posted Date
2019-05-07
Last Posted Date
2023-12-27
Lead Sponsor
West Virginia University
Target Recruit Count
84
Registration Number
NCT03939923
Locations
🇺🇸

WVU Medicine, Morgantown, West Virginia, United States

Sugammadex Versus Neostigmine for Reversal of Neuromuscular Blockade at the End of Kidney Transplantation Surgery

First Posted Date
2019-04-22
Last Posted Date
2024-06-26
Lead Sponsor
University of Colorado, Denver
Target Recruit Count
84
Registration Number
NCT03923556
Locations
🇺🇸

University of Colorado Hospital, Aurora, Colorado, United States

The Use of Sugammadex in the Critically Ill

First Posted Date
2019-01-03
Last Posted Date
2019-08-21
Lead Sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Target Recruit Count
50
Registration Number
NCT03791801
Locations
🇨🇦

McGill University Health Center, Montreal, Quebec, Canada

🇨🇦

MUHC, Montréal, Quebec, Canada

Impact of Sugammadex vs. Neostigmine Reversal on Post-Operative Recovery and Complications

First Posted Date
2018-09-20
Last Posted Date
2022-10-14
Lead Sponsor
University Health Network, Toronto
Target Recruit Count
120
Registration Number
NCT03679611
Locations
🇨🇦

Toronto Western Hospital, Toronto, Ontario, Canada

Reversal of Residual Neuromuscular Blockade at Train-of-four Ratio 0.3 With Sugammadex and Neostigmine

First Posted Date
2018-09-04
Last Posted Date
2020-08-11
Lead Sponsor
Guangzhou General Hospital of Guangzhou Military Command
Target Recruit Count
121
Registration Number
NCT03656614
Locations
🇨🇳

Guangzhou Military Region General Hospital, Department of Anesthesiology, Guangzhou, Guangdong, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy